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Abstract
Quantitative characterization of disease progression using longitudinal data can provide long-term predictions for the
pathological stages of individuals. This work studies the robust modeling of Alzheimer’s disease progression using
parametric methods. The proposed method linearly maps the individual’s age to a disease progression score (DPS) and
jointly fits constrained generalized logistic functions to the longitudinal dynamics of biomarkers as functions of the DPS
using M-estimation. Robustness of the estimates is quantified using bootstrapping via Monte Carlo resampling, and the
estimated inflection points of the fitted functions are used to temporally order the modeled biomarkers in the disease
course. Kernel density estimation is applied to the obtained DPSs for clinical status classification using a Bayesian
classifier. Different M-estimators and logistic functions, including a novel type proposed in this study, called modified
Stannard, are evaluated on the data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for robust modeling
of volumetric magnetic resonance imaging (MRI) and positron emission tomography (PET) biomarkers, cerebrospinal
fluid (CSF) measurements, as well as cognitive tests. The results show that the modified Stannard function fitted using
the logistic loss achieves the best modeling performance with an average normalized mean absolute error (NMAE) of
0.991 across all biomarkers and bootstraps. Applied to the ADNI test set, this model achieves a multiclass area under
the ROC curve (AUC) of 0.934 in clinical status classification. The obtained results for the proposed model outperform
almost all state-of-the-art results in predicting biomarker values and classifying clinical status. Finally, the experiments
show that the proposed model, trained using abundant ADNI data, generalizes well to data from the National Alzheimer’s
Coordinating Center (NACC) with an average NMAE of 1.182 and a multiclass AUC of 0.929.
Keywords: Alzheimer’s disease, disease progression modeling, M-estimation, generalized logistic function, kernel
density estimation, Bayesian classifier, magnetic resonance imaging, positron emission tomography, cerebrospinal fluid.
1. Introduction
Alzheimer’s disease (AD) is the most common type of
dementia and leads to progressive neurodegeneration, af-
fecting memory and behavior according to regional damage
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to the brain cells (Ewers et al., 2011). The hippocampus,
which is the center of learning and memory, is often one of
the first regions of the brain to be damaged. It has also been
shown that cerebrospinal fluid (CSF) biomarkers can be-
come abnormal in the presymptomatic phase of the disease,
preceding positron emission tomography (PET) and mag-
netic resonance imaging (MRI) biomarkers followed by
clinical markers (Jack Jr et al., 2010; Biagioni and Galvin,
2011). Currently, the cause of AD is not clear, and there
is no cure or effective treatment to stop its progression,
but early diagnosis of the disease, especially in the pre-
symptomatic stages, can provide time to treat symptoms
and plan for the future. However, early diagnosis of AD
is challenging mainly because elderly subjects can suffer
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Figure 1: An illustration of the AD progression modeling method proposed by Jedynak et al. (2012, 2015). Left: A Sigmoid function is fitted to the
biomarker measurements of each subject. Middle: The biomarker trajectories are aligned by linearly transforming subject age to DPS. Right: The
aligned biomarker fit is obtained for all subjects.
from different age-related pathologies and normal aging be-
sides AD. Therefore, methods to stage and identify at-risk
individuals are critical to dementia research.
Disease progression modeling uses longitudinal studies
to develop data-driven quantitative models that describe
the evolution of the disease over time. The approach can,
therefore, provide a complete perspective of the disease by
computationally exploring the available data to help with a
better understanding of the disease for diagnostic, staging,
monitorization, and prognostic purposes. Parametric dis-
ease progression modeling methods can be divided into two
categories, continuous fitting for modeling the dynamics of
biomarkers and discrete ordering for biomarker abnormal-
ity detection, both relying on unsupervised learning, e.g.,
by using maximum-likelihood estimation. The discrete
methods focus on temporally ordering of biomarkers be-
coming abnormal during the disease stages by discretizing
the disease progression trajectory using generative, event-
based models (Fonteijn et al., 2012; Venkatraghavan et al.,
2019).
Continuous parametric methods for modeling the pro-
gression of Alzheimer’s disease have been inspired by
hypothetical models assuming a sigmoidal evolution of
AD biomarkers (Jack Jr et al., 2010, 2013). The goal of
these methods is to model biomarker values as a function
of disease progression (Jedynak et al., 2012; Oxtoby and
Alexander, 2017). Accordingly, a variety of approaches
have been applied to fit a continuous function to the longitu-
dinal dynamics of each biomarker using statistical models
such as differential equations and mixed-effects models
(Oxtoby et al., 2014; Yau et al., 2015; Guerrero et al., 2016;
Bilgel et al., 2016; Li et al., 2019), in which one needs to
align the trajectory of individuals based on some time mea-
sure, e.g., time-to-conversion. These methods are simple
and require less data, but parametric assumptions on the
biomarker trajectories limit the flexibility of the fits.
Recently, nonparametric disease progression modeling
methods have been introduced to model biomarkers jointly
while taking temporal dependencies among measurements
into account using Gaussian processes (Lorenzi et al.,
2017) or deep learning (Ghazi et al., 2019). These methods
are flexible, make fewer assumptions for modeling, and do
not require alignment of the trajectories of the individuals.
However, a multivariate gaussian process with monotonic-
ity constraints is computationally expensive to fit due to
large covariance matrices, and deep learning methods are
less interpretable, hard to train in cases when the data is
sparse or irregular, and cannot easily be applied for predic-
tion when the unseen data has fewer biomarkers than what
was used for training.
Jedynak et al. (2012, 2015) proposed a parametric algo-
rithm, which requires less time-series data to train and in-
corporates information from multiple biomarkers for mod-
eling progression of AD over a common disease timescale.
As shown in Figure 1, the method linearly transforms
the age of the individual to a disease progression score
(DPS) for the time-wise alignment of within-cohort mea-
surements, assuming that the visit intervals in the data are
short relative to the disease duration. Alternating least
squares is applied to fit a sigmoid function to the longitudi-
nal dynamics of each biomarker. In this method, biomarker
trajectories are fitted independently and the biomarker de-
pendencies are only considered when the algorithm al-
ternates to estimate the subject-specific (age) parameters,
which in turn can cause difficulties for the convergence
of the alternating algorithm. Furthermore, the proposed
model is not robust to outliers that can be found in more
contaminated data. The first two problems have been tack-
led by Bilgel and Jedynak (2019), but the problem with
outliers remains.
Maximum likelihood type estimation (M-estimation) is
introduced as a robust regression method (Huber, 2004) to
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Figure 2: An illustration of how the proposed method (red curves) tackles the existing biomarker curve-fitting problems using simulated data
generated based on logistic functions and additive white Gaussian noise. Left: A flexible function is used to fit the asymmetric shape of the
simulated data points. Middle: A constrained function is utilized to estimate the exact dynamics of the biomarker. Right: A robust estimator is
applied to fit a curve to the simulated data contaminated with outliers.
cope with outliers by minimizing a loss function designed
to de-emphasize outliers (see Table 2). The model fit can
further be improved by utilizing a more flexible function
(see Table 1) and/or constraining the objective function.
However, increasing the number of parameters needs to
be penalized as it can increase the model complexity and
result in overfitting. Figure 2 illustrates 1) how the use of a
flexible function improves the curve fit, 2) how the use of
a constrained function moves lower and upper asymptotes
to fit the exact dynamics of the biomarker, and 3) how the
use of M-estimation reduces the influence of outliers.
In this paper, a robust extension of Jedynak et al. (2012,
2015) is proposed that jointly fits a constrained logistic
function to the longitudinal dynamics of each biomarker
using M-estimation to address the abovementioned curve-
fitting problems, e.g., outliers, in the biomarker modeling
(see Figure 2). The estimated parameters are quantified
using bootstrapping via Monte Carlo resampling, and the
inflection points are used to temporally order the biomark-
ers in the disease course. Kernel density estimation with
normal bases is applied to the estimated DPSs for clinical
status classification using a Bayesian classifier. Differ-
ent loss and logistic functions are considered, including a
modified version of the Stannard function (Stannard et al.,
1985) that tends to better describe the biomarker trajecto-
ries, and they are applied to AD progression modeling of
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
(Petersen et al., 2010) and the National Alzheimers Coor-
dinating Center (NACC) (Beekly et al., 2007) data using
volumetric MRI biomarkers, CSF and PET measurements,
and cognitive tests. The obtained results indicate that the
modified Stannard function fitted using the logistic loss
achieves the best modeling performance over different
bootstraps, and it consistently outperforms the basic algo-
rithm of Jedynak et al. (2015) and state-of-the-art results
of Bilgel and Jedynak (2019) and Marinescu et al. (2020)
in almost all experiments.
The main contribution of this study is four-fold. First,
we introduce a novel generalized logistic function, called
modified Stannard, which better fits the AD biomarker tra-
jectories compared to using other logistic functions. Sec-
ond, the use of M-estimation suppresses the effect of out-
liers on the fit. Third, the across-cohort generalizability
of the proposed model is evaluated by applying the model
trained using ADNI data to the test data from the NACC
cohort with fewer biomarkers. Finally, an end-to-end ap-
proach is introduced that performs biomarker trajectory
modeling (unsupervised learning), biomarker inflection
point detection (event ordering), and clinical status clas-
sification (supervised learning). This is a holistic way to
implement a system suitable for both research and clinical
applications to better study, detect, and monitor AD.
2. The proposed method
The main objective of this work is to minimize the error
of parametric disease progression modeling while mak-
ing the estimates stable and robust to outliers. This is
achieved by fitting a constrained logistic function using an
M-estimator.
2.1. Modeling dynamics of biomarkers
Two sets of parameters are estimated in the model: ob-
served biomarker-specific parameters, which are assigned
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Table 1: Details of the utilized logistic functions for AD progression modeling. Note that the range of each function can be controlled by two
additional parameters.
Logistic function g(s;θ) θ (min,max)∀ b > 0 g′(s;θ) g′′(c;θ)
Verhulst
[
1 + e−b(s−c)
]−1 {b, c} (0, 1) at (−∞,+∞) be−b(s−c) [1 + e−b(s−c)]−2 0
Gompertz e−e
−b(s−c) {b, c} (0, 1) at (−∞,+∞) be−b(s−c)e−e−b(s−c) 0
Richards
[
1 + γe−b(s−c)
]−1/γ {b, c, γ} (0, 1) at (−∞,+∞) be−b(s−c) [1 + γe−b(s−c)]−1−1/γ 0
Modified Stannard
[
1 + 1γ e
− bγ (s−c)
]−γ
{b, c, γ} (0, 1) at (−∞,+∞) bγ e−
b
γ (s−c)
[
1 + 1γ e
− bγ (s−c)
]−1−γ
0
for fitting the biomarker curves, and hidden subject-specific
(age-related) disease progression parameters that are de-
fined for aligning the trajectory of subjects. Assume that
yi,j,k is the k-th biomarker’s value at the j-th visit of the
i-th subject and f(s;θ) is an S-shaped logistic function of
DPS s with parameters θ. Each biomarker measurement is
defined as
yi,j,k = f(si,j ;θk) + σki,j,k ,
where σk is the standard deviation of the k-th biomarker
with θk parameters, i,j,k is additive white Gaussian noise
(random effect) with i.i.d. assumption, and si,j is the DPS
for the j-th visit of the i-th subject and is obtained as
si,j = αiti,j + βi ,
where ti,j is the age of subject i in visit j, and αi ∈ R>0
and βi ∈ R are the rate and onset of disease progression
of subject i, respectively. Finally, the multiobjective opti-
mization for robust nonlinear regression is defined as
{αˆ, βˆ, θˆ} = min
i,j,k
∑
i,j,k
wiρ
(
yi,j,k − f(αiti,j + βi;θk)
σk
)
,
where ρ(·) is a maximum likelihood-type function and
wi = 1/Ni is a weighting factor for normalizing the ob-
jective function with the number of available points per
subject (Ni).
For fitting the longitudinal trajectories of biomarkers,
four logistic functions are considered (Table 1). All func-
tions have the same range (0, 1) and can produce the same
inflection points at c ∈ R, to be later used for biomarker
ordering. We candidate utilization of a modified flexible
logistic function based on the Stannard function (Stannard
et al., 1985), where the 1/γ factor is multiplied by the ex-
ponential term to create an asymmetric growth curve with
an inflection point at c like other functions. This function
tends to better describe asymmetrical sigmoid patterns of
the biomarker trajectories with modeling both slow and
rapid growths at the beginning or the end of the disease
period. In the defined functions, b ∈ R>0 and γ ∈ R>0
denote the growth rate and symmetry parameter of the
curves, respectively. The reason for restricting b to the pos-
itive real numbers is to make parameters of the estimation
identifiable.
It can also be deduced from Table 1 that the sigmoid
function first introduced by Verhulst (Verhulst, 1845) is
a special (symmetric) case of both Richards’ function
(Richards, 1959) and the proposed function when γ = 1.
Moreover, Gompertz’s function (Gompertz, 1825) is a sim-
plified form of Richards’ function when γ approaches zero,
i.e., limγ→0(1 + γu)−1/γ = e−u. Finally, the upper and
lower asymptotes of the curves can be adjusted by two
additional parameters (Zwietering et al., 1990) as
f(s;θ) = (a− d)g(s;θ) + d .
The range parameters, a and d, can be set to fixed values
when the exact range of biomarkers is given, which is the
case with cognitive tests. This, in turn, not only reduces
the number of optimization parameters but also increases
the stability of the estimation. For other biomarkers, if
there are, for example, sign constraints which are the cases
with nonnegative CSF and PET measurements, both pa-
rameters can be constrained to lower and/or upper bounds,
but otherwise remain unconstrained.
2.2. Model fitting
Alternating approach, as an efficient optimization tech-
nique, is applied to solve the problem where the algorithm
iteratively estimates θ using fixed values of α and β and
vice versa until the parameters converge. The proposed
algorithm can be summarized as follows
Initialization: initialize {α(0),β(0), θ(0)} using mea-
surements.
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Table 2: The utilized ρ-type M-estimators and their corresponding scale
factors τ for robust regression.
Loss function ρ(r) τ
L2 r2 1
L1-L2 2
(√
1 + r2 − 1
)
1
Logistic ln(cosh(r)) 1.205
Modified Huber
{
1− cos(|r|), |r| ≤ pi/2
|r|+ (1− pi/2), |r| > pi/2 1.2107
Cauchy-Lorentz ln(1 + r2) 2.3849
Optimization: iterate l until convergence.
Biomarker fitting: estimate the biomarker-specific
parameters using values of all subjects and visits.
θˆ(l) = min
i,j,k
∑
i,j,k
wiρ
(
yi,j,k−f(αˆ(l−1)i ti,j+βˆ(l−1)i ;θk)
σk
)
, (1)
Age mapping: estimate the subject-specific parame-
ters using values of all biomarkers and visits.
{αˆ(l)i , βˆ(l)i } = min
(j,k)∈Ni
∑
j,k
wiρ
(
yi,j,k−f(αiti,j+βi;θˆ(l)k )
σk
)
, (2)
where Ni corresponds to the number of measurements
among all biomarkers and visits available for the i-th sub-
ject. This way, in contrast to Jedynak et al. (2012, 2015),
biomarkers are fitted jointly. The degrees of freedom of the
fit is equal to
∑
k(Nk−|θk|)−2I , whereNk is the number
of measurements among all subjects and visits available for
the k-th biomarker, |θk| denotes the number of biomarker-
specific parameters for the k-th biomarker, and I is the
number of subjects. Therefore, the algorithm can be ap-
plied in case the data contains more than
∑
k |θk| + 2I
points, and if any subject has at least two distinct points
considering all biomarkers and visits.
The utilized maximum likelihood-type functions for ro-
bust regression (Holland and Welsch, 1977; Pennacchi,
2008) are described in Table 2. These estimators attempt
to diminish the influence of the outliers while fitting curves.
In general, M-estimators use a tuning parameter called τ
to scale the functions as τ2ρ(r/τ) in order to yield 95%
asymptotic efficiency with respect to the standard normal
distribution. The corresponding tuning constants for the
utilized functions are also reported in Table 2.
Finally, the obtained DPSs are standardized with respect
to the scores of the available cognitively normal visits of
subjects in order to calibrate all biomarker trajectories in
different experiments. This process removes the mean of
the normal visits’ distribution of DPSs and scales the range
to give a better intuition of timing of disease progression
in the course of AD. In this case, it would be necessary to
properly update the parameters as
si,j = (si,j − µcn) /σcn ,
αi = αi/σcn ,
βi = (βi − µcn) /σcn ,
bk = σcnbk ,
ck = (ck − µcn) /σcn ,
where µcn and σcn are the mean and standard deviation
of the DPSs in the available cognitively normal visits of
subjects, respectively.
2.3. Biomarker value prediction
Biomarker values can be predicted using the fitted model
parameters. Age mapping part of the proposed algorithm
is applied to estimate the subject-specific parameters using
Equation (2) based on the values of those biomarkers of
the test subject that have available estimated biomarker-
specific parameters in the fitted model. Next, biomarker
values are predicted as f(si,j ;θk) using the estimated test
DPSs where f(·) is the logistic function applied to model
fitting.
2.4. Clinical status classification
In order to predict the clinical status of test subjects per
visit, kernel density estimation (KDE) (Parzen, 1962) is
used to fit the likelihoods of cognitively normal, cognitively
impaired, and AD groups in a nonparametric way. Assume
that (s1, s2, . . . , sN ) is a set of N i.i.d. DPSs sampled
from an unknown distribution with density function p(s|ci),
where ci denotes the i-th class label. KDE is expressed as
pˆ(s|ci) = 1
Nw
N∑
n=1
K
(
s− sn
w
)
,
whereK(·) is a smooth (kernel) function with a smoothing
bandwidth w > 0. Here, the Gaussian kernel is used as the
smoothing function.
The clinical status is classified based on the DPSs with
a Bayesian classifier that uses the KDE-based fitted likeli-
hoods as
p(ci|s) = p(ci)p(s|ci)∑
i
p(ci)p(s|ci) ,
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where p(ci) is the data-driven prior probability for the i-th
class, p(ci|s) is the posterior probability for predicting the
test DPS that belongs to the class ci, and the term in the
denominator specifies the evidence and can be dropped
because the maximum a posteriori estimation is used for
classification.
3. Experimental setup
3.1. Data
The data used in this work is obtained from the ADNI
and the NACC databases.
3.1.1. ADNI
The ADNI was launched in 2003 as a public-private part-
nership, led by principal investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether
serial MRI, PET, other biological markers, and clinical
and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment and
early Alzheimer’s disease. We use The Alzheimer’s Dis-
ease Prediction Of Longitudinal Evolution (TADPOLE)
challenge dataset (Marinescu et al., 2018) that includes
the three ADNI phases ADNI 1, ADNI GO, and ADNI
2. This dataset contains measurements from brain MRI,
PET, CSF, cognitive tests, and demographics, and genetic
information.
The labels cognitively normal (CN), significant mem-
ory concern (SMC), and normal (NL) are merged under
CN; mild cognitive impairment (MCI), early MCI (EMCI),
and late MCI (LMCI) under MCI; and AD and dementia
under AD. In addition, subjects converting from one clin-
ical status to another, e.g., MCI-to-AD, are assigned the
latter label (AD in this example). The utilized ADNI data
includes T1-weighted brain MRI volumes of ventricles,
hippocampus, whole brain, fusiform, and entorhinal cortex,
PET scan measures of fludeoxyglucose (FDG-PET) and
florbetapir (AV45-PET), CSF measures of Amyloid beta,
total tau, and phosphorylated tau, as well as the cognitive
tests of clinical dementia rating sum of boxes (CDR-SB),
Alzheimer’s disease assessment scale 13 items (ADAS-13),
mini-mental state examination (MMSE), functional activi-
ties questionnaire (FAQ), Montreal cognitive assessment
(MOCA), and Rey auditory verbal learning test of imme-
diate recall (RAVLT-IR). Detailed information about the
utilized biomarkers can be found in Table 7.
3.1.2. NACC
The NACC, established by the National Institute on Ag-
ing of the National Institutes of Health in 1999, has been
developing a large database of standardized clinical and
neuropathological data from both exploratory and explana-
tory Alzheimer’s disease research (Beekly et al., 2007).
The data has been collected from different Alzheimer’s
disease centers across the United States and among others
contains measurements from different modalities such as
MRI, PET, and cognitive tests.
Labels with numerical cognitive status of one (normal
cognition) and two (impaired-not-MCI) are merged under
CN, and cognitive status of three (MCI) and four (De-
mentia) are set to MCI and AD, respectively. It should
be noted that we only keep subjects with primary etio-
logic diagnosis of normal, AD, or missing. This is to
exclude subjects diagnosed with other types of dementia,
non-neurodegenerative disease, or a non-neurological con-
dition. The used NACC data includes T1-weighted brain
MRI volumes of hippocampus and whole brain, and the
cognitive tests of MMSE, MOCA, FAQ (sum of the 10-
item scores), and CDR-SB using the CDR R© Dementia
Staging Instrument.
3.1.3. Data filtering
For our analysis, in each of the ADNI and NACC
datasets, measurements outside known biomarker ranges,
e.g., RAVLT-IR < 0, are rejected and assumed as miss-
ing values. The volumetric MRI outliers observed in the
ADNI dataset are removed by assuming intracranial vol-
ume (ICV) estimates that are proportionally smaller than
estimated corresponding MRI measurements, i.e., MRI /
ICV > 1, as missing values.
Clinical follow-up visits with reverting clinical diag-
noses are removed per subject considering the neighbor-
ing visits. In the ADNI dataset, clinical follow-up vis-
its with wrongly ordered dates are discarded per subject.
Also, MRI, PET, and CSF measurements that are already
matched to the cognitive visits with any extreme time gaps
are excluded. The acceptable time gap is obtained based on
the data statistics and is set to three months. In the NACC
dataset, we perform the matching of MRI and clinical vis-
its. However, due to the relatively smaller sample size in
NACC compared with ADNI, matches more than three
months apart are kept and treated as two distinct visits. In
this analysis, we assign a missing clinical status for any
MRI visits that do not fall within the 3-month window.
In order to be able to apply the proposed method, mea-
surements and clinical diagnoses with missing date infor-
mation per visit are set to missing values, and subjects with
less than two distinct visits are omitted. This results in 219
ADNI subjects and 151 NACC subjects being excluded.
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Table 3: Demographics of the obtained datasets after filtering across visits.
clinical status age, year education, year MMSE
(mean±SD) (mean±SD) (mean±SD)
CN 76.93±6.03 15.76±2.92 29.05±1.20
MCI 75.07±7.67 15.80±2.90 27.43±2.26
AD 76.47±7.51 15.80±2.90 21.61±4.61AD
N
I
Missing 74.44±7.87 16.10±2.64 27.34±3.07
CN 79.06±7.34 13.76±4.00 28.46±1.71
MCI 80.83±8.57 13.79±4.03 25.32±3.03
AD 81.09±8.14 13.73±4.08 19.60±5.11NA
C
C
Missing 78.88±11.69 13.56±4.69 28.29±2.36
Note that missing clinical status after filtering is indicated as ‘Missing’.
Table 4: Statistics of the visits per dataset after filtering.
# visits per clinical status # visits per subject visit interval, year # measurements per subject
CN MCI AD Missing (mean±SD) (mean±SD) (mean±SD)
ADNI 2,285 3,850 2,064 899 5.99±2.37 0.74±0.43 58.60±23.38
NACC 1,140 205 318 9 7.00±2.91 1.15±0.37 21.61±9.03
3.1.4. The obtained study population
After filtering the data, the utilized 16 ADNI biomark-
ers are acquired from 1,518 subjects (854 males and 664
females) in 9,098 visits between August 2005 and May
2017, and the six NACC biomarkers are acquired from
239 subjects (75 males and 164 females) in 1,672 visits
between October 2005 and July 2018. All subjects in both
datasets have at least one cognitive test. In the NACC
data, 203 subjects underwent MRI imaging while in the
ADNI data, 1,515 and 1,220 subjects underwent MRI and
PET imaging, respectively, and 1,088 subjects have CSF
measures. Table 3 and Table 4 summarize statistics of
the demographics and measurements in the two datasets
after data filtering. Note that both datasets include missing
values and missing clinical status, the latter indicated as
‘Missing’.
3.1.5. Data preprocessing
In the ADNI dataset, the volumetric measurements
were obtained using two different versions of the public
FreeSurfer software package (Fischl et al., 2002), and in
the NACC dataset, they were calculated using IDeA Lab
following ADNI protocols. Therefore, the MRI measure-
ments need to be corrected for FreeSurfer version (Gro-
nenschild et al., 2012), software package, and hence for
different cohorts (ADNI-NACC). In addition, biological
difference in brain size hinders direct utilization of MRI
measurements for disease progression estimation. Total
intracranial volume (TIV) or ICV is a commonly used
measure for normalization to correct for head size. To
overcome both aforementioned problems of difference in
cohort/software (version) and head size, we employ the
residual approach (O’Brien et al., 2011) based on the anal-
ysis of covariance, which takes data from control groups
and linearly regresses MRI volumes on their corresponding
ICV as a covariate of interest. The corrected measurements
can thus be calculated as the estimated residuals Rˆ of the
volumes using the regression parameters obtained from the
control data as
Rˆi,j,k,v = ROIi,j,k,v −
[
βˆcnk,v + αˆ
cn
k,vICVi,j,k,v
]
,
where ROIi,j,k,v is the k-th MRI volume for subject i at
visit j calculated (observed) using software or software
version v, ICV is the corresponding intracranial volume,
and βˆcn and αˆcn are the intercept and slope of the regres-
sion estimated from the CN group. Finally, the estimated
residuals are standardized per cohort/software (version) so
that all variables have zero mean and unit variance.
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3.1.6. Data partitioning and bootstrapping
To evaluate the algorithms, each of the ADNI and NACC
datasets is partitioned into two non-overlapping sets for
training and testing. To be more specific, based on the
first and last available diagnoses of subjects, i.e., CN-CN,
CN-MCI, ..., AD-AD, we divide each of these types of
pairs into two groups including few and many visits using
the median number of visits as threshold and randomly
select 20% of the subjects from each group for testing.
Additionally, bootstrapping is used in the experiments
for quantification of the estimation, and in each boot-
strap, a subset of the training subjects is randomly sampled
with replacement based on the first and last available pair
of diagnoses and the number of available visits per sub-
ject, to make sure each bootstrap sampling contains data
from any diagnostic status and sequence lengths. The un-
used subjects are assigned for validation and account for
1/e ≈ 0.37 of the subjects where e is the base of the natural
logarithm. This also means that the estimated variance us-
ing the bootstrapped model will account for approximately
63% of the total variance.
To facilitate future research in AD progression modeling
and comparison with the current study, all the data splits,
including each bootstrap split, are also provided on arXiv
as ancillary files.
3.2. Evaluation metrics
Robust Bayesian information criterion (BIC) is used as
a criterion for model selection among the robust models
(Machado, 1993). The criterion is penalized with the num-
ber of parameters to avoid overfitting, where the model
with the lowest BIC is preferred, and it is defined as
BIC = 2E
(Lopt)
train +Q ln(N) ,
where E(Lopt)train is the training loss at the optimum itera-
tion number Lopt obtained through biomarker fitting using
Equations (1) and (2), N is the total number of measure-
ments, and Q is the total number of parameters which is
equal to
∑
k |θk|+ 2I .
The mean absolute error (MAE) is used to assess the
modeling performance as a measure less sensitive to out-
liers (Chai and Draxler, 2014). It is calculated based on the
absolute differences between actual and estimated values
as follows
MAE =
1
Nk
∑
(i,j)∈Nk
∣∣yi,j,k − f(si,j ;θk)∣∣ ,
where Nk is the number of measurements among all sub-
jects and visits available for the k-th biomarker, and yi,j,k
and f(si,j ;θk) are the ground-truth and estimated values
of the k-th biomarker for the i-th subject at the j-th visit.
Absolute errors of different biomarkers can be normalized
with the corresponding standard deviation of the biomark-
ers and averaged across all normalized biomarkers to ob-
tain a single performance measure called normalized MAE
(NMAE). The modeling performance of two different meth-
ods is statistically compared using the paired, two-sided
Wilcoxon signed-rank test (Wilcoxon, 1945) applied to the
NMAEs obtained from different bootstraps.
Additionally, multiclass area under the receiver oper-
ating characteristic (ROC) curve (AUC) (Hand and Till,
2001) is used to measure the diagnostic performance in
a multiclass test set and is calculated using the posterior
probabilities as
AUC = 1(nc(nc−1))
nc−1∑
i=1
nc∑
k=i+1
1
nink
[
SRi − ni(ni+1)2 + SRk − nk(nk+1)2
]
,
where nc is the number of distinct classes, ni denotes
the number of available observations belonging to the
i-th class, and SRi is the sum of the ranks of poste-
riors p(ci|si) after sorting all concatenated posteriors
{p(ci|si), p(ci|sk)} in an ascending order, where si and
sk are vectors of DPSs belonging to the true classes ci and
ck, respectively. Likewise, SRk is the sum of the ranks of
posteriors p(ck|sk) after sorting all concatenated posteriors
{p(ck|sk), p(ck|si)} in an ascending order.
3.3. Initialization of the algorithm and optimization
Since the fitting algorithm is iteratively performed using
an alternating approach starting from values optimized in
the previous step, initialization is an important step for
efficiently reaching the optimum. We initially set α(0) and
β(0) to 1 and 0, respectively. Moreover, we initialize the
slope of the trajectories (λ) to either −1 or 1 depending
on the diagnoses. A positive slope is considered when
the average of the k-th biomarker’s values for cognitively
normal visits is less than that for AD visits and vice versa.
Next, the parameters of the logistic functions are initially
estimated as γk = 1, ck = 0, and bk = 4λk/(ak − dk),
where dk and ak are the minimum and maximum of the
k-th biomarker’s values, respectively, provided that the
slope λk is positive, and vice versa if the slope is negative.
Finally, we repeat the alternating procedure using the lo-
gistic functions and the trust-region algorithm (Coleman
and Li, 1996) considering robust estimators for at most 30
iterations.
3.4. Stopping criteria
To avoid overfitting, the optimal parameter values are
selected according to the optimum generalization loss ob-
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tained using the following criteria (Prechelt, 1998)
{αˆ, βˆ, θˆ} = min
Lmin≤l≤Lmax
E
(l)
valid ,
where E(l)valid is the validation loss at the l-th iteration ob-
tained through biomarker fitting using Equations (1) and
(2). The minimum number of iterations, Lmin, is set to
10 to allow for enough training progress. The maximum
number of iterations, Lmax, is set to 50. This avoids un-
necessary computations since it was empirically observed
that Evalid attained a minimum well within this iteration
range in all cases.
4. Results and discussion
4.1. Biomarker modeling
First, the proposed method is applied to model the dy-
namics of the ADNI biomarkers. Table 5 illustrates the
modeling performance (BIC) for ADNI training subsets ob-
tained from 100 bootstraps using different logistic and loss
functions. The combination of the modified Stannard func-
tion for biomarker fitting and the logistic loss achieve the
best modeling performance with both the lowest average
BIC and the smallest standard deviation and a validation
NMAE of 0.985± 0.029. This configuration will be used
in all the remaining experiments.
To further investigate the stability and robustness of
the model with the chosen configuration of logistic and
loss functions, we visualize the fitted trajectories for each
of the 100-bootstrap runs together with their average per
biomarker in Figure 3.
4.2. Temporal ordering of biomarkers
To indicate the timing and the dynamics of the differ-
ent biomarkers relative to each other, Figure 4 shows the
average curves scaled to [0, 1] using the estimated upper
and lower asymptotes per biomarker and superimposed in
the same figure. The distribution of the inflection points of
the biomarkers, quantified through bootstrapping, can be
used to see how biomarkers proceed in the course of AD
with respect to each other. The inflection point is consid-
ered a turning point at which the direction of biomarker
curvature changes. Figure 5 displays the temporal ordering
of the ADNI biomarkers based on the estimated inflec-
tion points. As can be seen, CSF and PET biomarkers, as
well as RAVLT-IR, precede all other biomarkers followed
by MRI biomarkers and cognitive tests. These findings
are in line with the results of Jedynak et al. (2012, 2015);
Young et al. (2015); Bilgel and Jedynak (2019). More in-
terestingly, RAVLT-IR starts becoming abnormal early in
the disease course which is consistent with several clini-
cal studies concluding that some cognitive tests including
RAVLT are significant predictors that can predict neurode-
generative changes up to 10 years before clinical diagnosis
(Tierney et al., 2005; Landau et al., 2010; Zandifar et al.,
2019). However, some of the MRI biomarkers such as
the ventricles and whole-brain are noisy measurements for
modeling the progression of AD in this dataset, as also
seen in Figure 5. It is important to note that the inflection
points are utilized to order the biomarkers in the disease
course. These points do not measure when the biomarkers
start becoming abnormal and hence, cannot be used for
early abnormality detection.
4.3. DPS distribution versus biomarker timing
Figure 6 shows the variance of the estimated inflec-
tion points per biomarker alongside the estimated class-
conditional likelihoods of the obtained DPSs from 100
bootstraps. As can be seen, there are moderate overlaps
between the DPS distributions of CN-MCI and MCI-AD
Table 5: Modeling performance as BIC (mean±SD) ×104 for the 100-times bootstrapped ADNI training subsets using different logistic and
loss functions.
PPPPPPPPPPPP
Logistic
function
Loss function
L2 L1-L2 Logistic Modified Huber Cauchy-Lorentz
Verhulst 2.090±0.039 1.901±0.028 1.830±0.027 1.836±0.027 1.925±0.029
Gompertz 2.101±0.042 1.902±0.028 1.831±0.027 1.836±0.027 1.927±0.029
Richards 2.077±0.038 1.899±0.028 1.829±0.027 1.835±0.027 1.924±0.029
Modified Stannard 2.077±0.038 1.898±0.028 1.828±0.026 1.834±0.027 1.924±0.028
The best result is shown in boldface and its corresponding configuration is selected for the remaining experiments.
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Figure 3: Estimated curves per bootstrap (in gray) for the ADNI biomarkers using the modified Stannard function and the logistic loss. The average
of the bootstrapped curves per biomarker is shown as the black curve.
while the CN and AD groups can be discriminated easily.
Moreover, the estimated inflection points per biomarker
are almost in line with those of the hypothetical model
by Jack Jr et al. (2010) that illustrates when biomarkers
are dynamic versus disease stages. Especially, inflection
points of the MRI biomarkers (brain structure) are mainly
located in the MCI stage while those of the cognitive tests
(memory), except for RAVLT-IR, lie on the AD stage.
4.4. Predicting biomarker values
The biomarker-specific parameters estimated using the
bootstrapped training set are applied to map the ages of
test individuals to DPSs using Equation (2). The obtained
DPSs are then fed to the estimated biomarker functions
in each bootstrap. Table 6 shows the test NMAEs of the
100-times bootstrapped ADNI dataset for the proposed
model and the analogous model by Jedynak et al. (2015)
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Figure 4: The average of the normalized curves of the ADNI biomarkers across 100 bootstraps.
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Figure 5: Temporal ordering of the ADNI biomarkers in the disease
course obtained using inflection points and quantified through 100 boot-
straps. The values in the matrix represent the frequency of occurrences
(probabilities) and the units in the x-axis indicate the relative ordering
of the biomarkers.
that independently fits the basic sigmoid function using
an unconstrained, L2-norm loss function. The proposed
model significantly (p < 0.001) outperforms the analogous
model with an average NMAE of 0.991 vs. 1.552 and an
average BIC of 1.828×104 vs. 3.303×104. Table 7 shows
the average test MAE per biomarker across 100 bootstraps.
4.5. classifying clinical status
To evaluate the diagnostic predictive performance,
the obtained training DPSs are used to estimate class-
conditional likelihood functions per bootstrap using KDE
and fed to a three-class Bayesian classifier with prior proba-
bilities proportional to the number of training observations
in each class. The classifiers, one for each bootstrap, are ap-
plied to the test DPSs estimated as described in Section 4.4
to compute the posterior probabilities of the clinical labels.
The proposed model achieves an AUC of 0.931± 0.004 in
classifying the clinical status of the test ADNI subjects per
visit, which reveals the effect of modeling on classification
performance.
The obtained posterior probabilities from the different
classifiers can be combined using ensemble learning tech-
niques to potentially improve prediction performance and
Table 6: Test modeling performance of different methods as NMAE (mean±SD) for ADNI and NACC biomarkers. Note that ADNI has 16
biomarkers while NACC has only 6 biomarkers in common between the two datasets. All the NMAEs are significantly different (p < 0.001).
Within cohort Across cohort
Method ADNI NACC ADNI to NACC
Jedynak et al. (2015) 1.552±0.069 1.040±0.210 2.665±0.311
The proposed method 0.991±0.023 0.833±0.061 1.182±0.087
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Table 7: Detailed information about the utilized ADNI biomarkers.
Biomarker Interpretation Unit Range Inflection point Test MAE
(median) (mean)
CDR-SB The sum of scores of six sets of
questions. Lower values indicate
less cognitive dysfunction.
Cognitive score [0, 18] 3.003 0.562
ADAS-13 The sum of scores of 13 itemized
tasks. Lower values indicate less
cognitive dysfunction.
Cognitive score [0, 85] 3.596 4.236
MMSE The sum of scores of a set of
questions. Lower values indicate
more cognitive dysfunction.
Cognitive score [0, 30] 3.552 1.506
FAQ The sum of scores of 10 sets of
questions. Lower values indicate
less cognitive dysfunction.
Cognitive score [0, 30] 2.264 1.415
MOCA The sum of scores of 30 ques-
tions. Lower values indicate
more cognitive dysfunction.
Cognitive score [0, 30] 3.363 2.154
RAVLT-IR The sum of scores from five tri-
als in remembering a list of 15
words immediately after each
trial. Lower values indicate more
cognitive dysfunction.
Cognitive score [0, 75] 1.600 5.983
CSF amyloid-beta The concentration level of brain
beta-amyloid protein. Lower val-
ues indicate more concentration.
Picograms per
milliliter
(0,∞) 1.591 374.4
CSF total tau and
phosphorylated tau
The concentration level of neu-
rofibrillary tangles of brain tau
protein. Lower values indicate
less concentration.
Picograms per
milliliter
(0,∞) 1.811
1.600
95.19
10.10
FDG-PET The regional cerebral metabolic
rate of glucose. Lower values in-
dicate less activity.
Standardized up-
take value ratio
(0,∞) 2.995 0.104
AV45-PET The cerebral amyloid deposition.
Lower values indicate less depo-
sition.
Standardized up-
take value ratio
(0,∞) 1.591 0.151
Adjusted T1-
weighted brain
MRI volumes of
ventricles, hip-
pocampus, whole
brain, fusiform, and
entorhinal cortex
The regional brain atrophies. Ex-
cept in the case of ventricles,
lower values indicate more atro-
phy.
Standardized
volume residual
(−∞,∞) 2.385
1.600
2.328
1.973
2.461
0.899
0.791
0.716
0.883
0.789
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Figure 6: Estimated class-conditional likelihoods using the DPSs ob-
tained from 100 ADNI-trained bootstraps. The box plots indicate the
25th to 75th percentiles of the estimated inflection points per biomarker,
centrally marked with the median, and they are extended to the most
extreme non-outlier inflection points using dashed lines.
robustness (Kuncheva, 2014). For example, by fusing
the posteriors based on taking the average of the within-
class posteriors over an ensemble of models from different
bootstraps (bagging), the AUC of the proposed method
increases to 0.934.
4.6. Comparison with state-of-the-art results
In order to fairly compare our results with those of state-
of-the-art methods, we apply the proposed method to the
TADPOLE training and test subsets of D1 and D2 using the
same 16 ADNI biomarkers. The proposed model achieves
an average AUC of 0.937 which is on a par with the best
performance of TADPOLE with an average AUC of 0.931
(Marinescu et al., 2020). Besides, our obtained average
MAE of 3.93 for ADAS-13 outperforms the best reported
result with an average MAE of 4.70. However, the pro-
posed model does not perform well on the normalized
ventricles compared to the best reported result with an
average MAE of 0.0086 vs.0.0041.
Next, we employ the same ADNI data splits and
biomarkers as used by Bilgel and Jedynak (2019) and make
a head-to-head comparison with the results reported in the
aforementioned study. This also enables a head-to-head
comparison with both Li et al. (2019) and Lorenzi et al.
(2017) based on their results reported by Bilgel and Jedy-
nak (2019). To do so, biomarker trajectories need to be de-
scribed as a function of time-from-AD-conversion. Hence,
inspired by Bilgel and Jedynak (2019), we select any sub-
jects converting to AD and calculate the time from AD
conversion using the difference between the visiting age
and the age at which the first AD status is diagnosed. The
corresponding DPSs are then mapped to the obtained times
from the AD conversion of the selected subjects using a
linear regression model. These estimates can later be used
to calculate the time-from-AD-conversion for any subjects
visits using the estimated DPSs. Since the time-from-AD-
conversion is a linear function of DPS, i.e., mˆ0 + mˆ1si,j ,
we can adjust the biomarker parameters as bk = bk/mˆ1
and ck = mˆ0 + mˆ1ck to obtain biomarker trajectories as
a function of time-from-AD-conversion. The obtained re-
sults indicate that the proposed model outperforms Bilgel
and Jedynak (2019) with a root-mean-square-error of 0.68
vs. 1.48; yet it has a larger maximum absolute error (4.20
vs. 3.79).
4.7. Generalizability across cohorts
As the final set of experiments, the generalizability of
the proposed model to an independent cohort is assessed
using the NACC data. First, the same configuration of
logistic function and M-estimator, i.e., the modified Stan-
nard and logistic loss is applied to model the progression
of AD within NACC. Figure 7 depicts the modeled NACC
biomarkers for 100 bootstraps. Second, the optimal model
previously trained on ADNI is utilized to predict the NACC
test measurements using the estimates of the common
ADNI-NACC biomarkers, i.e., CDR-SB, MMSE, FAQ,
MOCA, hippocampus, and whole brain. Table 6 com-
pares the modeling performance of the ADNI-trained and
NACC-trained models applied to the NACC test set. As
it can be noticed from the obtained results, the previously
selected configuration for training ADNI data is also a
good choice when applied to NACC data. Moreover, the
proposed model significantly (p < 0.001) outperforms the
analogous model of Jedynak et al. (2015) in all cases. Ad-
ditionally, modeling performance of the proposed method
degrades less than that of the analogous model of Jedynak
et al. (2015) when applying the ADNI-trained model to
the NACC test set, which indicates the generalizability
of the proposed method across cohorts. It should also be
noted that the utilized NACC subset have fewer biomark-
ers and measurements than the used ADNI subset, which
likely is the reason why it results in a smaller within-cohort
modeling error.
We also apply the ADNI and NACC trained classifiers
to the estimated test NACC DPSs to classify the clinical
status per subject per visit. The proposed method achieves
AUCs of 0.929 ± 0.012 and 0.928 ± 0.016, respectively.
This reveals that diagnostic performance improves when
applying the ADNI-trained model to the NACC test set.
5. Conclusions
In this paper, a robust parametric model of Alzheimer’s
disease progression was proposed based on alternating M-
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Figure 7: Estimated curves per bootstrap (in gray) for the NACC biomarkers using the modified Stannard function and the logistic loss. The average
of the bootstrapped curves per biomarker is shown as the black curve. The last subfigure shows the average of the normalized curves of the NACC
biomarkers across 100 bootstraps.
estimation using the logistic loss to address potential curve-
fitting problems such as outliers. The proposed method
linearly transformed individuals’ ages to disease progres-
sion scores and jointly fitted modified Stannard functions
to the longitudinal dynamics of biomarkers. The estimated
parameters were then used to temporally order the biomark-
ers in the disease course and to predict biomarker values
as well as to classify the clinical status per subject visit in
an independent test set. The obtained results showed the
superiority of the proposed method over the state-of-the-art
results in terms of prediction performance, and this method
generalizes well across cohorts.
The proposed approach can be applied to different time-
series data including missing data points and labels, or
to biomarkers with other characteristics than the mono-
tonic behavior that one typically encounters in, for exam-
ple, neurodegenerative disease progression modeling using
MRI/PET biomarkers, as long as suitable functions are
used for biomarker modeling. Moreover, as an alterna-
tive to using M-estimators, resistant estimators such as the
least trimmed sum of squares and least median of squares
(Rousseeuw and Leroy, 1987) with higher breakdown
points can be used to fit biomarker trajectories. Though,
this will result in an additional parameter to be optimized
for the coverage (range) needed for trimming the residuals.
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